Quantité totale PI	241
Rang # Quantité totale PI	5 339
Note d'activité PI	2,6/5.0    50
Rang # Activité PI	14 632
Classe Nice dominante	Produits pharmaceutiques, vétéri...

Brevets Marques 148 10 31 2 48 1 1
Dernier brevet	2024 - Crystalline forms of a bruton's ...
Premier brevet	1989 - Photodynamic activity of sapphyrins
Dernière marque	2020 - ACT ACKNOWLEDGE COMMUNICATE TRACK
Première marque	1993 - PHARMACYCLICS

Industrie (Classification de Nice)

Derniers inventions, produits et services 2024 Invention Crystalline forms of a bruton's tyrosine kinase inhibitor. Described herein is the Bruton's tyro... 2023 Invention Inhibitors of bruton's tyrosine kinase. Disclosed herein are compounds that form covalent bonds ... Invention Inhibitors of bruton's tyrosine kinase. Described herein are irreversible kinase inhibitor compo... Invention Methods of treating and preventing graft versus host disease. Described herein are methods for t... Invention Methods of treating and preventing alloantibody driven chronic graft versus host disease. Descri... Invention Methods of treating abc-dlbcl using inhibitors of brutons tyrosine kinase. Disclosed herein are ... Invention Synthesis of a bruton's tyrosine kinase inhibitor. Described herein is the synthesis of Bruton's... Invention Use of inhibitors of brutons tyrosine kinase (btk). Disclosed herein are methods for treating a ... 2021 Invention Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor. Described herein are pharma... Invention Co-crystals of a bruton's tyrosine kinase inhibitor. Disclosed are co-crystals of the Bruton's t... Invention Crystalline forms of a brutons tyrosine kinase inhibitor. Described herein is the Bruton's tyros... Invention Solvated forms of a bruton's tyrosine kinase inhibitor. Described herein are solvates of the Bru... 2020 Invention Use of inhibitors of brutons tyrosine kinase (btk). Methods are provided for treating a hematolo... P/S Medical services, namely, disease management programs; providing health information; telehealth s... P/S medical services, namely, disease management programs; providing health information; telehealth s... Invention Crystalline forms of a bruton's tyrosine kinase inhibitor. Described herein is the Bruton's tyros... Invention Use of inhibitors of brutons tyrosine kinase (btk). Disclosed herein are methods for treating a c... Invention Methods for the treatment of her2 amplified cancer. Described herein are methods and composition... Invention Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor. Described herein are pharmac... Invention Crystalline forms of a brutons tyrosine kinase inhibitor. Described herein is the Bruton's tyrosi... Invention Treatment using bruton's tyrosine kinase inhibitors and immunotherapy. Combinations of Bruton's ... Invention Use of inhibitors of bruton's tyrosine kinase (btk). Disclosed herein are methods for treating a ... 2019 Invention Solvated forms of a bruton?s tyrosine kinase inhibitor. Described herein are solvates of the Bru... Invention Salts of 3-[(dimethylamino)methyl]-n-{2-[4-(hydroxycarbamoyl) phenoxy]ethyli-1-benzofuran-2-carbo... Invention Methods of treating and preventing graft versus host disease. Described herein are methods for tr... Invention Ibrutinib combination therapy. Combinations of Bruton's tyrosine kinase (Btk) inhibitors, e.g., ... Invention Inhibitors of brutons tyrosine kinase. Disclosed herein are reversible and irreversible inhibito... Invention Tec family kinase inhibitor adjuvant therapy. Described herein are methods and compositions comp... Invention Inhibitors of brutons tyrosine kinase. Described herein are irreversible kinase inhibitor compou... Invention Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors. Described herein are i... Invention Bruton's tyrosine kinase inhibitor combinations and uses thereof. Disclosed arc compositions, me... 2014 P/S Pharmaceuticals; pharmaceutical preparations for the treatment of cancer, immune mediated disease... 2013 P/S Pharmaceuticals for the treatment of cancer 2012 P/S Pharmaceutical preparations for the treatment of cancer 2009 P/S Pharmaceutical preparations for the treatment of cancer, immune mediated diseases, inflammatory d... P/S Pharmaceutical preparations for the treatment of cancer, immune mediated diseases, inflammatory ... P/S pharmaceutical preparations for the treatment of cancer, immune mediated diseases, inflammatory d... 2000 P/S Pharmaceuticals for diagnosis and treatment of cancer. 1993 P/S pharmaceuticals used as [ magnetic resonance imaging contrast agents and ] therapeutics for cance...